Kindeva Drug Delivery Milestones in Injectable Fill-Finish
Kindeva Drug Delivery, a prominent global contract development and manufacturing organization (CDMO), recently made significant advancements at its state-of-the-art facility. They announced the successful completion of their first registration batch utilizing the high-volume vial line, a notable milestone reflecting the firm’s capabilities in injectable fill-finish processes.
Facility Enhancements for Increased Production
This achievement highlights Kindeva's commitment to expanding its capacity to meet the growing global demand for injectable drugs. The Bridgeton facility is now fully prepared for larger production volumes, positioning Kindeva as a leader in the industry.
Denis Johnson, the Chief Operating Officer, emphasized the importance of this development, stating, "The completion of the first registration batch at the Bridgeton facility represents a significant milestone. This is just the beginning, as we plan for the installation of three additional lines over the coming year and a half. Furthermore, we have successfully concluded the Factory Acceptance Testing (FAT) for the first of two cutting-edge Optima syringe and cartridge filling lines designed for our new facility."
Upcoming Production Lines and Their Impact
Kindeva anticipates that the first Optima line will arrive soon, with operational qualification expected to occur in early 2025. By the end of that year, the company aims to have both Optima lines fully certified for production. This strategic expansion is forecasted to enable Kindeva to manufacture over 100 million units annually across various formats, including vials, syringes, and cartridges.
Engagement with Industry Professionals
To foster collaboration, Kindeva invites industry professionals and potential partners to visit them at Booth #7D50 during the CPHI Worldwide conference in Milan. This event will provide an opportunity for attendees to explore Kindeva’s new facility, which adheres to stringent Annex 1 compliance standards, ensuring the highest quality in aseptic processes.
About Kindeva Drug Delivery
Kindeva Drug Delivery excels as a global leader in the CDMO domain, specializing in sterile injectables, pulmonary, nasal, transdermal, and intradermal solutions. With a focus on innovation and quality, Kindeva is dedicated to transforming healthcare through advanced manufacturing capabilities. They provide comprehensive services spanning development and manufacturing to analytical capabilities, supporting a wide array of drug delivery formats.
The organization is keenly focused on overcoming industry challenges through strategic investments in cutting-edge technologies. These initiatives include expanding their aseptic injectable fill-finish operations and pioneering environmentally friendly propellant solutions. Kindeva maintains a robust presence across the U.S. and the U.K., with a diverse client portfolio that strengthens their global impact.
Frequently Asked Questions
What recent milestones did Kindeva Drug Delivery achieve?
Kindeva has successfully completed its first registration batch at its Bridgeton facility, showcasing its readiness for increased production in injectables.
What are the new production lines at Kindeva?
Kindeva is introducing Optima syringe and cartridge filling lines, which are crucial for enhancing production capacity for injectable drugs.
When are the new filling lines expected to be operational?
The first Optima line is scheduled to arrive in November 2024, with expectations of full qualification by the end of Q1 2025.
Where can industry professionals see Kindeva’s new facility?
Professionals can visit Kindeva’s Booth #7D50 at the CPHI Worldwide conference in Milan for insights into their operations.
What distinguishes Kindeva in the drug delivery industry?
Kindeva is recognized for its commitment to innovation, quality, and proactive responses to industry challenges, making it a trusted partner in drug delivery.
